1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Cardiff Aims To Change Standard Of Care For Some Colorectal Cancers

 
• By Jessica Merrill

Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer demonstrated impressive early efficacy and underpinned a $40m fundraising for the company.

(Shutterstock)
Key Takeaways
  • Cardiff believes the PLK1 inhibitor onvansertib could be a new standard of care for RAS-mutant first-line metastatic colorectal cancer in combination with chemotherapy and bevacizumab.

 

Cardiff Oncology believes it is on track to upend the standard of care for patients with RAS-mutated metastatic colorectal cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.